WINSTON-SALEM, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the following two upcoming healthcare conferences in September: Citi Biopharma Back to School Conference (Boston)Date:Wednesday, September 3, 2025Time:10:30am ETFormat:Fireside ChatWebcast:Link Morgan Stanley ...

Core Viewpoint - ProKidney Corp. is actively engaging with investors through participation in the H.C. Wainwright 4 Annual Kidney Virtual Conference, highlighting its focus on chronic kidney disease and its innovative cellular therapy approach [1]. Company Overview - ProKidney Corp. is a pioneer in chronic kidney disease treatment through cellular therapy innovations, founded in 2015 after a decade of research [2]. - The company's lead product candidate, rilparencel (REACT), is a first-in-class autologous cellular therapy currently in Phase 2 and Phase 3 studies aimed at preserving kidney function in diabetic patients at high risk of kidney failure [2]. - Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, indicating its potential significance in the treatment landscape [2].

Core Points - ProKidney Corp. has completed the domestication process, changing its jurisdiction of incorporation from the Cayman Islands to Delaware, effective July 1, 2025 [1] - Shareholders approved the domestication at the Annual General Meeting on May 29, 2025, with Class A and Class B ordinary shares converting to common stock [1] - ProKidney's common stock will begin trading on Nasdaq under the unchanged symbol "PROK" starting July 2, 2025 [1] - The company does not expect any impact on day-to-day business operations due to the domestication [1] Company Overview - ProKidney is focused on chronic kidney disease (CKD) and is a pioneer in cellular therapy, founded in 2015 after a decade of research [3] - The lead product candidate, rilparencel (REACT), is a first-in-class autologous cellular therapy in Phase 2 and Phase 3 studies aimed at preserving kidney function in diabetic patients at high risk of kidney failure [3] - Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA [3]

Core Insights - ProKidney Corp. reported financial results for Q1 2025, highlighting its focus on chronic kidney disease (CKD) and upcoming milestones in clinical trials [1][2] Financial Highlights - As of March 31, 2025, ProKidney had cash, cash equivalents, and marketable securities totaling $328.5 million, down from $358.3 million at the end of 2024, which is expected to fund operations into mid-2027 [4][8] - Research and development expenses were $27.3 million for Q1 2025, slightly up from $27.2 million in Q1 2024, with increases in cash compensation and facility costs offset by a decrease in clinical trial costs [5] - General and administrative expenses rose to $14.4 million in Q1 2025 from $12.8 million in Q1 2024, primarily due to higher cash compensation and professional fees [6] - The net loss before noncontrolling interest was $38.0 million for Q1 2025, compared to $35.3 million for the same period in 2024 [7] Clinical Development - The company is approaching key milestones, including the release of full Group 1 data from the Phase 2 REGEN-007 study and a regulatory update on the accelerated approval pathway for rilparencel following a Type B meeting with the FDA [2][8] - Full data from Group 1 of the Phase 2 REGEN-007 study is expected in Q2 2025, involving approximately 20 patients with an average follow-up of 18 months [9] - The Phase 3 REGEN-006 (PROACT 1) clinical trial is ongoing, focusing on patients with type 2 diabetes and advanced CKD, with a total planned enrollment of approximately 685 subjects [10] Company Overview - ProKidney Corp. specializes in cellular therapeutics for chronic kidney disease, with its lead product candidate, rilparencel, being evaluated in late-stage clinical trials [12]